Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215675 | 0.92 | MGLL (0.35) | MGLLKMT2AMEN1LMNACNR1 | |
| SCHEMBL23216075 | 0.91 | MGLL (0.36) | MGLLKMT2AMEN1LMNACNR1 | |
| SCHEMBL23215940 | 0.90 | TACR3 (0.39) | MGLLKMT2AMEN1LMNACNR1 | |
| SCHEMBL23215038 | 0.89 | MGLL (0.38) | MGLL | |
| SCHEMBL23216325 | 0.88 | CCR4 (0.35) | MGLLKMT2AMEN1LMNADPP4 | |
| SCHEMBL23215237 | 0.88 | CCR4 (0.35) | MGLLKMT2AMEN1LMNADPP4 | |
| Trifluoroacetic Acid SCHEMBL23215332 | 0.84 | DPP4 (0.36) | MGLLCNR1NPSR1DPP4DPP7 | |
| Trifluoroacetic Acid SCHEMBL23215328 | 0.84 | DPP4 (0.36) | MGLLCNR1NPSR1DPP4DPP7 | |
| SCHEMBL23215346 | 0.83 | DPP4 (0.34) | CNR1DPP4DPP7 | |
| SCHEMBL23230903 | 0.82 | CNR1 (0.37) | MGLLKMT2ACNR1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | MGLL 3399/4885KMT2A 229/4885MEN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.